



Final Appraisal Recommendation

Advice No: 0912 – May 2012

**Midazolam (BUCCOLAM[®]▼) 2.5 mg, 5 mg, 7.5 mg and 10 mg
oromucosal solution**

Submission by Shire Pharmaceuticals Ltd

Recommendation of AWMSG

Midazolam (BUCCOLAM[®]▼) is recommended as an option for use within NHS Wales for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). For infants between 3–6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

Midazolam (BUCCOLAM[®]▼) should be prescribed by brand name to reduce the risk of medication errors.

Additional note:

- AWMSG is of the opinion that midazolam (BUCCOLAM[®]▼) may be appropriate for use within NHS Wales prescribed under specialist recommendation.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), lay/patient/carer perspective (where available) and discussions at AWMSG.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	ViroPharma Ltd
Date of first issue	May 2012
Last reviewed	August 2016



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0912:
Midazolam (BUCCOLAM[®]▼) 2.5 mg, 5 mg, 7.5 mg and 10 mg oromucosal solution. May 2012.

